Navigation Links
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Date:7/12/2011

ies inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking StatementsThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future financial performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's product candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Rege
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.
2. Sanofi Enters Into Research Collaboration with Weill Cornell Medical College to Discover New Treatments for Tuberculosis
3. Sanofi Pasteur Commends Winners of International BioGENEius Challenge
4. Sanofi Announces Positive Results from the "All to Target" Study Evaluating Two Lantus® and Apidra® Regimens Versus Premixed Regimen
5. Medco, United BioSource and Sanofi Signed Global Agreement to Improve Quality of Patient Care Through Real-World Evidence
6. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
7. Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims
8. sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
9. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants
10. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
11. Sanofi-Aventis Completes Acquisition of Genzyme Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... MALVERN, Pa. , April 27, 2015 /PRNewswire/ ... development and commercialization of products focused on the ... executive team of William Stewart and ... mark important steps in SCILEX,s proprietary drug development ... of its products. The Company,s first product, ZTlido™ ...
(Date:4/27/2015)... 27, 2015 Harwood Feffer LLP ( www.hfesq.com ... directors of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") ... breached its fiduciary duties to shareholders. On ... announcing results from its first Phase 3 registration trial ... that in the trial, Rhopressa failed to meet its ...
(Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
Breaking Medicine Technology:SCILEX Pharmaceuticals Announces Commercial Executive Appointments 2SCILEX Pharmaceuticals Announces Commercial Executive Appointments 3Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2
... March 06, 2007 /PRNewswire/ -- Up to two ... up to 600,000,hospitalized. Its primary complication, pulmonary embolism ... than breast cancer and,AIDS combined. People who suffer ... DVT, because these factors also heighten the,likelihood of ...
... POZEN Inc.,(NASDAQ: POZN), today announced top-line results of its ... of 2006. PA 325 is a patented formulation of ... immediate release,formulation of a proton pump inhibitor., The PA ... subjects,over the age of 50. Each subject was treated ...
Cached Medicine Technology:DVT Awareness Survey Findings: Heart and Respiratory Patients 2POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 2POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 3
(Date:4/27/2015)... The Doctors on Liens mission for over ... attorneys with the best doctors working on a lien basis. ... their history and that trend continues with the addition of ... in the Tujunga / Sunland area. Featuring ... can find comprehensive care and detailed documentation of their injuries. ...
(Date:4/27/2015)... Sitting or standing for long periods of time can ... those whose occupation requires them to be sitting while they ... to be on their feet for most of the day, ... severe and longer lasting. These people suffer from a condition ... Northeast Houston Vein Center is offering tips on how to ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Data Integrity ... Within Your Operations or Your Partners/Suppliers, **FDAnews Webinar**, May ... http://www.fdanews.com/DataIntegrity , Data integrity issues have become ... few years., Uncovering data integrity issues within manufacturing operations ... integrity issues come to light, remediating them can be ...
(Date:4/27/2015)... Columbus, OH (PRWEB) April 27, 2015 ... insurance to help his clients feel secure, but also helps ... a.m. to 7 p.m., Douglas will be manning a booth ... Expo Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... this worthy event that will feature hundreds of adoptable pets ...
(Date:4/27/2015)... A' Design Award and Competition is pleased ... by Boombang Inc Design Team has been announced as ... Scientific Instruments, Medical Devices and Research Equipment Design ... Boombang Inc Design Team, the creative team behind the ... Image Lumica is a two-way communication device between patients ...
Breaking Medicine News(10 mins):Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 4Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2Health News:Boombang Inc Design Team wins Platinum in A' Medical Product Design Awards 2
... one of the largest studies in hormone receptor positive ... , PHILADELPHIA, Dec. 11 New ... (lapatinib) plus Femara(R) (letrozole) versus letrozole alone as ... metastatic breast cancer. In the study, women diagnosed with ...
... BOSTON, Dec. 11 The American Federation for,Medical Research ... Tom Daschle,s appointment to the post of Health and ... top,administration official to overhaul the nation,s health care system. ... result of its work since 1940, the AFMR believes ...
... by Matthew L. Myers, President, Campaign for Tobacco-Free Kids: , ... , , It is good ... Future survey released today finds that smoking rates among 8th, ... recorded in this survey for all three grades. However, ...
... released the following statement today on President-elect Obama,s nomination of ... and Human Services and naming him the Director of a ... , "Tom Daschle,s nomination as Secretary of ... the new White House Office of Health Reform is great ...
... among teens is slowing, survey finds , , THURSDAY, Dec. 11 ... among teens, the abuse of painkillers such as Vicodin and ... decline in the use of drugs such as marijuana has ... National Institute on Drug Abuse says in its report, ...
... Midwest Flooding, Indiana Tornadoes , , ... top five disasters of 2008, based on the number of people ... Gustav, Hurricane Ike, the flooding in the Midwest, and the tornadoes ... Weather played a disastrous part in many people,s lives in ...
Cached Medicine News:Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 4Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 5Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 6Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 7Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 2Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 3Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 4Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 2Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 3Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 4Health News:10% of U.S. High School Seniors Use Vicodin 2Health News:10% of U.S. High School Seniors Use Vicodin 3Health News:Red Cross Announces Top Five Disaster Responses of 2008 2
Radianse indoor positioning supports healthcare asset management with a way to locate medical equipment, devices and other portable assets....
Agility has delivered a RFID-enabled mobile asset management program....
Agility can provide tracking and management of surgical instruments, instrument trays and case carts to significantly enhance the current central sterile department flow by improving efficiency....
Assetrac allows identification, location, and protection of your assets....
Medicine Products: